S1P is a largely extracellular lipid that is necessary for correct immune cell positioning.  While disrupting S1P receptor signaling with S1P receptor modulating (SRM) drugs is useful in treating autoimmune diseases, these drugs are broadly immunosuppressive and they have significant side effects including initial dose bradycardia.  S1P Therapeutics’ approach is to inhibit the S1P transporter, Spns2. The Company’s S1P transport blockers have anti-inflammatory and anti-fibrotic activities in kidney disease models without the toxicities of S1P receptor modulators.